William A. Curran

Davis Polk advised Natura Cosméticos S.A. in connection with its $750 million offering of 5.375% senior notes due 2023, which were issued pursuant to Rule 144A and Regulation S under the…

Davis Polk is advising the joint lead arrangers, joint bookrunners and the administrative agent in connection with a $2.5 billion unsecured bridge facility to be…

Davis Polk advised the representative of the initial purchasers on a Rule 144A/Regulation S offering by Continental Resources, Inc. of $1 billion aggregate principal amount of its 4…

Davis Polk advised the joint book-running managers in connection with the initial public offering of 30,000,000 units of Regalwood Global Energy Ltd. for aggregate proceeds of $300…

Davis Polk is advising Aetna on its approximately $77 billion acquisition by CVS Health. The transaction, which is expected to close in the second half of 2018, is subject to approval by…

Davis Polk advised the representatives of the initial purchasers in connection with a Rule 144A/Regulation S offering by SRC Energy Inc. of $550 million aggregate principal amount of 6…

Davis Polk advised the representatives of the several underwriters in connection with Bandwidth Inc.’s initial public offering of 4,000,000 shares of Class A common stock, at $20.00…

Davis Polk advised the joint book-running managers in connection with an SEC-registered common stock offering of 40,250,000 shares of common stock of SRC Energy, Inc. Included in the…

Davis Polk is advising Advanced Accelerator Applications S.A. on its $3.9 billion acquisition by Novartis. Entry into the definitive agreement has been approved by the board of…

Davis Polk advised Auris Medical Holding AG in connection with the SEC-registered offering of $1.5 million of its common shares to Lincoln Park Capital Fund, LLC. The common shares are…